Fig. 1: Effect of apalutamide treatment on efficacy endpoints across age groups in TITAN and SPARTAN. | British Journal of Cancer

Fig. 1: Effect of apalutamide treatment on efficacy endpoints across age groups in TITAN and SPARTAN.

From: Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Fig. 1: Effect of apalutamide treatment on efficacy endpoints across age groups in TITAN and SPARTAN.The alternative text for this image may have been generated using AI.

a Radiographic progression-free survival (TITAN) and metastasis-free survival (SPARTAN). b Overall survival. Bars represent 95% CI. APA apalutamide, CI confidence interval, HR hazard ratio, MFS metastasis-free survival, NR not reached, PBO placebo, rPFS radiographic progression-free survival.

Back to article page